News >

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

Angelica Welch
Published: Tuesday, Nov 21, 2017

Jonathan Ledermann MD, FRCP

Jonathan Ledermann MD, FRCP
Checkpoint inhibitors are charging ahead in the race toward immunotherapy in the treatment of patients with ovarian cancer. Although studies are still in their early days, there seems to be emerging promise, said Jonathan Ledermann, MD.

during the 2017 ESGO Congress, Ledermann, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discussed the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

OncLive: What is the status of immunotherapy in the treatment of patients with ovarian cancer?

Ledermann: To summarize, there are now single-agent studies with 4 of the checkpoint inhibitors that have been tested in ovarian cancer. At the moment, we are still at a very early stage in understanding the data. Only 1 of those [trials] has been published; the others have been presented.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication